Fermanagh Weight Loss Clinic
If you have recently started Mounjaro in Northern Ireland, or are considering it, one of the first questions you are likely asking is how quickly it will work. The honest answer is that it depends, and not just on the medication itself. At Fermanagh Clinics, we have seen a clear pattern emerge between patients who engage fully with their treatment plan and those who rely on the injection alone. This blog walks through what the timeline typically looks like, and more importantly, what the patients who get the best results actually do differently. Book a consultation or contact our team to get started.
Most patients notice a reduction in appetite within the first one to two weeks of starting Mounjaro. Measurable weight loss typically begins within the first four weeks, with more significant results building over three to six months as the dose increases. Patients who combine Mounjaro with dietary changes, regular movement, and clinical support consistently achieve faster, greater, and longer-lasting results than those who make no lifestyle changes at all.
Meet Two Hypothetical Patients: Sarah And Mark
To illustrate what makes the real difference with Mounjaro, consider two hypothetical patients. Both are adults living in Northern Ireland, both start Mounjaro at the same time, and both have a similar starting weight. The difference is in how they approach the treatment.
Sarah books a consultation at Fermanagh Clinics, attends follow-up appointments, follows the titration schedule, makes gradual dietary changes, and stays in contact with our team when she has questions or side effects.
Mark starts Mounjaro but does not seek ongoing support. He makes no changes to his diet or activity levels and does not follow up with a clinician after his initial prescription.
Both will likely lose weight. But as you will see, the journey and the outcome look very different.
The Mounjaro Titration Schedule: What To Expect
Mounjaro is started at a low dose and increased gradually over several months. This process, known as titration, is designed to allow the body to adjust to the medication and to minimise side effects. The standard schedule is outlined below.
| Phase | Dose | Duration | What To Expect |
|---|---|---|---|
| Starting dose | 2.5mg | Weeks 1 to 4 | Appetite begins to reduce, mild side effects possible, early weight loss may begin |
| First increase | 5mg | Weeks 5 to 8 | Appetite suppression strengthens, weight loss typically becomes more noticeable |
| Second increase | 7.5mg | Weeks 9 to 12 | Continued weight loss, most patients feel well-adjusted to the medication by this point |
| Third increase | 10mg | Weeks 13 to 16 | Stronger appetite reduction, meaningful weight loss building steadily |
| Fourth increase | 12.5mg | Weeks 17 to 20 | Approaching maximum therapeutic effect for many patients |
| Maximum dose | 15mg | Week 21 onwards | Maximum appetite suppression and greatest potential for weight loss |
Weeks One To Four: The Starting Phase
Sarah (with clinical support) attends her initial consultation at Fermanagh Clinics, where our team explains what to expect at 2.5mg. She is advised to eat smaller portions, increase her protein intake, and avoid high-fat meals during the first few weeks. She is given guidance on injection technique and told to keep a consistent injection day each week.
During this phase, Sarah notices her appetite dropping noticeably by week two. She feels fuller after smaller meals and finds it easier to avoid snacking in the evenings. She experiences some mild nausea after her first two injections, but following our advice to eat slowly and avoid rich foods, this settles by week three. By the end of week four, she has lost approximately 2 to 3kg.
Mark (without support) starts his injections at home without any dietary guidance. He continues eating the same foods in the same quantities, reasoning that the medication will do the work. He experiences more significant nausea because he is still eating large, fatty meals. He loses a small amount of weight in the first month, but does not feel much different day to day.
Months Two To Three: Building Momentum
Sarah moves up to 5mg and then 7.5mg under the guidance of our team. She has started a daily 30-minute walk and has swapped several processed meals for home-cooked alternatives. She attends a brief follow-up with our team, who confirm her progress is on track and discuss managing a brief period of constipation with increased water intake and fibre.
By the end of month three, Sarah has lost approximately 8 to 10kg. Crucially, she is building habits around eating and movement that are starting to feel natural rather than forced.
Mark increases his dose based on the schedule printed with his medication, without clinical input. He does not notice the constipation as a manageable side effect and instead finds the treatment uncomfortable. He considers stopping. His weight loss over the same period is approximately 4 to 5kg, roughly half that of Sarah, and he has not made any meaningful changes to his lifestyle.
Months Four To Six And Beyond: The Divergence
This is where the gap between the two approaches becomes most apparent.
Sarah is now on 10mg, progressing towards 12.5mg. She has lost over 15kg and reports that her relationship with food has genuinely shifted. She is eating far less automatically, not through willpower, but because her appetite has changed. She sleeps better, has more energy, and has begun attending a weekly fitness class.
Mark has lost weight too, around 8 to 10kg, but he is struggling. His eating habits have not changed, and he has begun to notice that the appetite suppression feels less dramatic as he adjusts to the medication. He is not building any of the habits that would sustain his results.
The critical difference becomes clear when both patients eventually consider stopping treatment:
- Sarah has built sustainable dietary and activity habits that will support weight maintenance after treatment ends
- Mark has not changed his underlying behaviours and is at significantly greater risk of regaining the weight he lost
- Clinical evidence consistently shows that weight regain after stopping GLP-1 or dual agonist treatment is common without supporting lifestyle changes
- The medication creates a window of opportunity. What you do with that window determines your long-term outcome
What Successful Patients Do Differently: A Summary
| Area | With Clinical Support (Sarah) | Without Support (Mark) |
|---|---|---|
| Titration | Guided by a clinician, adjusted based on response | Self-managed, no individual review |
| Side effect management | Addressed promptly with practical advice | Unmanaged, increases risk of stopping early |
| Nutrition | Gradual, sustainable dietary improvements | No changes, same eating habits throughout |
| Physical activity | Introduced gradually, built into routine | None added |
| Weight loss (6 months) | Approximately 15 to 20kg | Approximately 8 to 10kg |
| Long-term outlook | Habits in place to maintain results after treatment | High risk of regaining weight after stopping |
Frequently Asked Questions
Most patients notice a reduction in appetite within the first one to two weeks. Visible weight loss typically follows within the first month, though the pace varies between individuals. Appetite suppression tends to strengthen as the dose increases over time.
Nausea is the most commonly reported side effect and is usually worst in the early weeks. Eating smaller meals, avoiding high-fat foods, staying hydrated, and eating slowly can all help. If side effects are persistent or troublesome, contact our team. In some cases, staying at the current dose for an extra week before titrating up can make a significant difference. Always discuss any changes to your titration schedule with your clinician before adjusting.
Research shows that weight regain after stopping treatment is common, particularly for patients who have not made lasting lifestyle changes during treatment. This is why we place significant emphasis on building sustainable habits alongside the medication itself. The injection reduces hunger and cravings, which creates an ideal opportunity to establish new patterns of eating and activity.
No. Many patients achieve excellent results at lower maintenance doses. The goal is not to reach the highest dose but to find the dose that delivers consistent, manageable weight loss with minimal side effects. Our team will help you identify that point through regular reviews.
Yes. We welcome self-referrals from patients across Northern Ireland. You do not need a letter from your GP. We carry out a full clinical assessment at your first appointment to confirm that Mounjaro is appropriate for you before any prescription is issued.
Alternative Weight Loss Medications
If Mounjaro is not the right fit for you, we offer a range of alternative medically supervised weight loss treatments at Fermanagh Clinics, and our team will help you find the one that suits your health profile and goals.
Wegovy (Semaglutide)
Wegovy contains semaglutide and works by activating GLP-1 receptors in the body, reducing appetite, slowing gastric emptying, and supporting blood sugar regulation. It is administered as a once-weekly injection and has a well-established track record in weight management. Clinical trials (the STEP programme) demonstrated average weight loss of approximately 15% of body weight at the 2.4mg maintenance dose. Wegovy also has dedicated cardiovascular outcomes evidence, making it a particularly relevant option for patients with existing heart disease or related risk factors. It is a well-tolerated, widely used treatment and a strong choice for patients at the earlier stages of their weight loss journey.
Saxenda (Liraglutide)
Saxenda contains liraglutide, another GLP-1 receptor agonist, and was one of the first injectable weight loss treatments to receive approval for obesity management. Unlike Mounjaro and Wegovy, Saxenda is administered as a once-daily injection rather than once weekly. It is titrated gradually from 0.6mg up to a maintenance dose of 3mg. Clinical trials showed average weight loss of approximately 5 to 8% of body weight. While the overall weight loss is more modest than newer treatments, Saxenda has a longer safety record and may be suitable for patients who have used it previously, or for whom the newer options are not clinically appropriate. It remains a well-evidenced and regulated prescription treatment.
NewWeigh
NewWeigh is a comprehensive weight loss programme based on meal replacement plans that provide all the essential nutrients your body needs while significantly reducing your calorie intake. These plans are designed to promote rapid and effective weight loss, helping you achieve your goals in a safe, structured, and supervised manner. NewWeigh products come in a variety of shakes, soups, and bars, making it easier to stick to your plan. It is particularly well suited to patients who want a stepped or holistic approach, or who may not meet the clinical criteria for injectable treatments. Our team can advise whether NewWeigh is appropriate for you and how it fits alongside other treatment options we offer.
Orlistat
Orlistat is an oral weight loss medication that works differently to injectable treatments. Rather than acting on appetite hormones, it reduces the amount of dietary fat absorbed by the gut, with approximately one third of fat passing through the body undigested. It is taken with meals up to three times daily and is typically recommended alongside a reduced-calorie, lower-fat diet. Orlistat is one of the longest-established prescription weight loss treatments available and has a well-understood safety profile. It tends to be most effective for patients who are committed to dietary changes and who prefer an oral medication over injections. Average weight loss is more modest than GLP-1 or dual agonist treatments, but it remains a clinically appropriate option for certain patients.
The most effective treatment for you depends on your medical history, current health conditions, weight loss goals, and personal preferences, which is why speaking with a clinician before starting any treatment is so important. Get in touch with our team at Fermanagh Clinics and we will help you find the right path forward.
Ready To Start Your Mounjaro Journey The Right Way?
If you are based in Northern Ireland and want the support that gives you the best possible chance of long-term success, we are here to help. At Fermanagh Clinics, our team will guide you through every stage of your weight loss treatment, from your first injection to your long-term maintenance plan.
- Phone: 028 6862 1828
- Email: thepillboxpharmacy@gmail.com
- Address: 24 Church Street, Irvinestown, Fermanagh, BT94 1EH
Book your consultation today and take the first step towards results that last.